BGM Group (BGM) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Journey Medical (DERM) has outperformed BGM Group (BGM) over the past year, losing 21.2% versus a loss of 96.8%. Journey Medical is the larger company by market cap ($167.9 million vs $133.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | DERM |
|---|---|---|
| Share price | $9.96 | $5.95 |
| Market cap | $133.01M | $167.94M |
| 1-day change | +6.07% | 0.00% |
| YTD return | -91.52% | -22.83% |
| 1-year return | -96.77% | -21.19% |
| 5-year return | -98.42% | — |
| EPS (TTM) | $-4.80 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $9.56 |
| 52-week low | $6.45 | $4.31 |
| Distance from 52-week high | -96.71% | -37.73% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +131.09% |
| Average volume | 6.13K | 182.16K |
| Shares outstanding | 12.69M | 22.22M |
| Employees | — | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed BGM by 75.6 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
BGM vs DERM FAQ
Which is bigger, BGM Group or Journey Medical?
Journey Medical (DERM) is larger, with a market capitalization of $167.94M compared with $133.01M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or DERM?
DERM returned -21.19% over the past 12 months, compared with -96.77% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.